09/11-2017 13:12:30: (PHO) Photocure ASA: Clinical and cost impact analysis shows beneficial impact of replacing current surgical modalities with Cevira
A poster demonstrating the clinical and cost impact of Cevira® was presented at
the ISPOR European congress in Glasgow, Scotland, November 4-8, 2017. The budget
impact model from a US payer perspective shows beneficial impact of replacing
the current surgical modalities, LEEP and cold knife conization, with Cevira®.
Photocure ASA announced today that a poster on the clinical and cost impact of
Cevira® from a US payer perspective was presented at the International Society
for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European
Congress, Glasgow, Scotland, November 4-8, 2017. The results show that Cevira®
at a unit price of 2500USD is cost neutral compared to the standard of care
surgical methods, loop electrosurgical excision procedure (LEEP) and cold knife
conization (CKC), or cost beneficial when the impact of preterm births is taken
into consideration.
Link to ISPOR web-site. Poster A26: http://bit.ly/2hg8PIz
These data come from a budget impact model developed from the perspective of a
US payer with a base case patient population from 5 million covered lives. The
model captured all Medicare costs for cervical cancer screening, diagnosis,
treatment and follow-up using 2016 reimbursement rates. Clinical data used in
the model were all from peer-reviewed published analyses. A scenario analysis
determined the impact of each of the treatment modalities (Cevira®, LEEP, CKC)
on preterm births and associated costs.
“This well designed and robust health economic model analysis demonstrates the
potential clinical and cost benefits of a non-surgical modality like Cevira® for
women with high-grade squamous intraepithelial lesions (HSIL, CIN2/3) of the
cervix. The Phase 2b trial showed solid safety and efficacy data, and the
convenient and easy-to-use integrated drug-light device was highly appreciated
both by the patients and the gynecologists participating in the study”, said
Professor and Chair, Mark H. Einstein, Department of OB/GYN & Women’s Health,
Clinical Research Unit, Rutgers New Jersey Medical School.
“It is very encouraging to see that the budget impact model shows Cevira®to be
valuable both from a clinical and cost perspective compared to current standard
of care in the US. The surgical modalities have increased risk of side effects,
including a higher risk of preterm births, and this is an enormous burden on the
society. When taking into account direct medical costs over the first year only,
the model shows that replacing the surgical methods with Cevira® will reduce
costs significantly”, commented Kjetil Hestdal, M.D., Ph.D., President and CEO,
Photocure ASA.
About Cevira®
Cevira® is a unique, non-invasive photodynamic therapy under development for the
treatment of oncogenic human papilloma virus (HPV) infection and pre-cancerous
cervical abnormalities.
For further information, please contact:
Photocure
